>
Neuren Pharmaceuticals logo

NEU - Neuren Pharmaceuticals Share Price

A$1.38 0.0  2.2%

Last Trade - 5:16am

Sector
Healthcare
Size
Small Cap
Market Cap £88.2m
Enterprise Value £74.8m
Revenue £81.7k
Position in Universe 710th / 1899
Bullish
Bearish
Unlock NEU Revenue
Momentum
Relative Strength (%)
1m -0.27%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -26.8%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
2.01 1.49 0.047 13.8 0.39 0.15 1.00 59.4 -40.7%
-12.8
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, NeurenPharmaceuticals Ltd revenues decreased 62% to A$147K. Netloss decreased 15% to A$9.2M. Revenues reflect a decreasein demand for the Company's products and services due tounfavorable market conditions. Lower net loss reflectsResearch and development costs decrease of 21% to A$7.8M(expense), FV Adjustments of Financial Investments decreasefrom A$261K (expense) to A$0K.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

NEU Revenue Unlock NEU Revenue

Net Income

NEU Net Income Unlock NEU Revenue

Normalised EPS

NEU Normalised EPS Unlock NEU Revenue

PE Ratio Range

NEU PE Ratio Range Unlock NEU Revenue

Dividend Yield Range

NEU Dividend Yield Range Unlock NEU Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
NEU EPS Forecasts Unlock NEU Revenue
Profile Summary

Neuren Pharmaceuticals Limited (Neuren) is a biopharmaceutical company engaged in developing drugs for neurological disorders. The Company develops therapies for brain injury, neurodevelopmental and neurodegenerative disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. Its products include NNZ-2566 and NNZ-2591. Its lead product, NNZ-2566 (Trofinetide), is in Phase II trial for the treatment of Rett syndrome, Fragile X syndrome, moderate to severe Traumatic Brain Injury (TBI) and Concussion. Trofinetide is an analog of a molecule, which is derived from insulin-like growth factor-1 (IGF-1) and occurs naturally in the brain. Its NNZ-2591 product is in Pre-clinical and Phase I trial for the treatment of other neurological conditions. Its subsidiaries include Hamilton Pharmaceuticals Inc. and Neuren Pharmaceuticals Inc.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated December 17, 2001
Public Since February 3, 2005
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 117,608,108
Free Float (0.0%)
Eligible for
ISAs
SIPPs
NEU Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for NEU
Upcoming Events for NEU
Tuesday 29th June, 2021 Estimate
Neuren Pharmaceuticals Ltd Annual Shareholders Meeting
Frequently Asked Questions for Neuren Pharmaceuticals
What is the Neuren Pharmaceuticals share price?

As of 5:16am, shares in Neuren Pharmaceuticals are trading at A$1.38, giving the company a market capitalisation of £88.2m. This share price information is delayed by 15 minutes.

How has the Neuren Pharmaceuticals share price performed this year?

Shares in Neuren Pharmaceuticals are currently trading at A$1.38 and the price has moved by 0.37% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Neuren Pharmaceuticals price has moved by -23.59% over the past year.

What are the analyst and broker recommendations for Neuren Pharmaceuticals?

Of the analysts with advisory recommendations for Neuren Pharmaceuticals, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Neuren Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Neuren Pharmaceuticals next release its financial results?

Neuren Pharmaceuticals is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Neuren Pharmaceuticals dividend yield?

Neuren Pharmaceuticals does not currently pay a dividend.

Does Neuren Pharmaceuticals pay a dividend?

Neuren Pharmaceuticals does not currently pay a dividend.

When does Neuren Pharmaceuticals next pay dividends?

Neuren Pharmaceuticals does not currently pay a dividend.

How do I buy Neuren Pharmaceuticals shares?

To buy shares in Neuren Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Neuren Pharmaceuticals?

Shares in Neuren Pharmaceuticals are currently trading at A$1.38, giving the company a market capitalisation of £88.2m.

Where are Neuren Pharmaceuticals shares listed? Where are Neuren Pharmaceuticals shares listed?

Here are the trading details for Neuren Pharmaceuticals:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: NEU
What kind of share is Neuren Pharmaceuticals?

Based on an overall assessment of its quality, value and momentum, Neuren Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Neuren Pharmaceuticals share price forecast 2021?

Shares in Neuren Pharmaceuticals are currently priced at A$1.38. At that level they are trading at 0.13% discount to the analyst consensus target price of 0.00.

Analysts covering Neuren Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -0.083 for the next financial year.

How can I tell whether the Neuren Pharmaceuticals share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Neuren Pharmaceuticals. Over the past six months, the relative strength of its shares against the market has been 8.62%. At the current price of A$1.38, shares in Neuren Pharmaceuticals are trading at 5.9% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Neuren Pharmaceuticals PE Ratio?

We were not able to find PE ratio data for Neuren Pharmaceuticals.

Who are the key directors of Neuren Pharmaceuticals?

Neuren Pharmaceuticals's management team is headed by:

Trevor Scott - NID
Joseph Horrigan - VPR
Larry Glass - CSO
Jon Pilcher - CEO
James Shaw - VOP
Dianne Angus - NID
Patrick Davies - NEC
Jenny Harry - NID
Lauren Frazer - CFO
Who are the major shareholders of Neuren Pharmaceuticals?

Here are the top five shareholders of Neuren Pharmaceuticals based on the size of their shareholding:

Cameron Richard Pty. Ltd. Corporation
Percentage owned: 5.07% (5.82m shares)
Scott (Trevor Donald) Individual Investor
Percentage owned: 3.13% (3.59m shares)
Stuart Andrew Pty. Ltd. Corporation
Percentage owned: 2.3% (2.63m shares)
Linwierik Super Pty. Ltd. Corporation
Percentage owned: 2.21% (2.54m shares)
Smithley Super Pty. Ltd. Corporation
Percentage owned: 1.85% (2.12m shares)
Similar to NEU
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.